Tuesday, 19 March 2024


Inovio Pharma secures $56M in funding

11 April 2018 | News

The agreement, providing funding over a five-year period, also includes options to establish investigational stockpiles of both vaccines.

Singapore - Inovio Pharmaceuticals is up 6% premarket on average volume on the heels of its announcement that the Coalition for Epidemic Preparedness Innovations (CEPI) will provide up the $56M in funding to support the development of vaccines against Lassa fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700) through Phase 2.

The agreement, providing funding over a five-year period, also includes options to establish investigational stockpiles of both vaccines.

CEPI is a partnership between public, private, philanthropic and civil organizations founded in Davos last year.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account